Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 66,300 shares, a drop of 96.4% from the December 15th total of 1,840,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.4% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. acquired a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned approximately 0.54% of Palisade Bio at the end of the most recent reporting period. 11.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Brookline Capital Management initiated coverage on shares of Palisade Bio in a research note on Wednesday, November 20th. They issued a “buy” rating and a $38.00 target price on the stock. Maxim Group lowered their price target on Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Palisade Bio Trading Down 4.4 %

Shares of NASDAQ:PALI traded down $0.08 on Tuesday, hitting $1.75. The company had a trading volume of 249,795 shares, compared to its average volume of 423,926. The company has a market cap of $4.84 million, a PE ratio of -0.13 and a beta of 1.42. The business has a 50 day moving average of $2.07 and a 200 day moving average of $3.14. Palisade Bio has a 52-week low of $1.38 and a 52-week high of $22.35.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter, beating the consensus estimate of ($3.35) by $1.03. As a group, equities analysts predict that Palisade Bio will post -12.43 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.